IL72740A - Adjuvant compositions comprising polyoxypropylene-polyoxyethylene block polymers,vaccine compositions containing them and methods for enhancing the immunogenicity of antigens - Google Patents

Adjuvant compositions comprising polyoxypropylene-polyoxyethylene block polymers,vaccine compositions containing them and methods for enhancing the immunogenicity of antigens

Info

Publication number: IL72740A
Authority: IL; Israel
Prior art keywords: amount; polyoxypropylene; volume; immunogenicity; antigens
Prior art date: 1983-08-22

Application number

IL72740A

Other languages

English (en)

Other versions

IL72740A0 (en

Original Assignee

Syntex Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-08-22

Filing date

1984-08-21

Publication date

1988-02-29

1984-08-21 Application filed by Syntex Inc filed Critical Syntex Inc

1984-11-30 Publication of IL72740A0 publication Critical patent/IL72740A0/xx

1988-02-29 Publication of IL72740A publication Critical patent/IL72740A/xx

Links

239000000203 mixture Substances 0.000 title abstract 4
229920003171 Poly (ethylene oxide) Polymers 0.000 title abstract 2
239000002671 adjuvant Substances 0.000 title abstract 2
239000000427 antigen Substances 0.000 title abstract 2
102000036639 antigens Human genes 0.000 title abstract 2
108091007433 antigens Proteins 0.000 title abstract 2
229920000642 polymer Polymers 0.000 title abstract 2
229960005486 vaccine Drugs 0.000 title abstract 2
230000002708 enhancing effect Effects 0.000 title 1
230000005847 immunogenicity Effects 0.000 title 1
231100000252 nontoxic Toxicity 0.000 abstract 2
230000003000 nontoxic effect Effects 0.000 abstract 2
DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 abstract 1
102000002068 Glycopeptides Human genes 0.000 abstract 1
108010015899 Glycopeptides Proteins 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 abstract 1
230000002434 immunopotentiative effect Effects 0.000 abstract 1
230000003308 immunostimulating effect Effects 0.000 abstract 1
239000011780 sodium chloride Substances 0.000 abstract 1
239000004094 surface-active agent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/5555—Muramyl dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S516/00—Colloid systems and wetting agents; subcombinations thereof; processes of
- Y10S516/01—Wetting, emulsifying, dispersing, or stabilizing agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S516/00—Colloid systems and wetting agents; subcombinations thereof; processes of
- Y10S516/01—Wetting, emulsifying, dispersing, or stabilizing agents
- Y10S516/02—Organic and inorganic agents containing, except water
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Mycology (AREA)
Biophysics (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Microbiology (AREA)
Dispersion Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Compositions Of Macromolecular Compounds (AREA)
Medicinal Preparation (AREA)
Polyethers (AREA)
Cosmetics (AREA)
Lubricants (AREA)

IL72740A 1983-08-22 1984-08-21 Adjuvant compositions comprising polyoxypropylene-polyoxyethylene block polymers,vaccine compositions containing them and methods for enhancing the immunogenicity of antigens IL72740A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US06/525,190 US4606918A (en)	1983-08-22	1983-08-22	Polyoxypropylene-polyoxyethylene block polymer based adjuvants

Publications (2)

Publication Number	Publication Date
IL72740A0 IL72740A0 (en)	1984-11-30
IL72740A true IL72740A (en)	1988-02-29

Family

ID=24092296

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL72740A IL72740A (en)	1983-08-22	1984-08-21	Adjuvant compositions comprising polyoxypropylene-polyoxyethylene block polymers,vaccine compositions containing them and methods for enhancing the immunogenicity of antigens

Country Status (14)

Country	Link
US (1)	US4606918A (de)
EP (1)	EP0135376B1 (de)
JP (2)	JPH0617314B2 (de)
AT (1)	ATE58062T1 (de)
AU (1)	AU578907B2 (de)
CA (1)	CA1236017A (de)
DE (1)	DE3483553D1 (de)
DK (1)	DK167173B1 (de)
HK (1)	HK82392A (de)
IE (1)	IE58035B1 (de)
IL (1)	IL72740A (de)
NZ (1)	NZ209293A (de)
PH (1)	PH21112A (de)
ZA (1)	ZA846504B (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4933179A (en) *	1983-08-22	1990-06-12	Syntex (U.S.A.) Inc.	Feline leukemia virus antigen vaccines
US4606918A (en) *	1983-08-22	1986-08-19	Syntex (U.S.A.) Inc.	Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4857318A (en) *	1983-11-07	1989-08-15	Syntex (U.S.A.) Inc.	Bordetella bronchiseptica pilus subunit protein vaccine effective against bordetella pertussis
US5171568A (en) *	1984-04-06	1992-12-15	Chiron Corporation	Recombinant herpes simplex gb-gd vaccine
US5244792A (en) *	1984-04-06	1993-09-14	Chiron Corporation	Expression of recombinant glyoprotein B from herpes simplex virus
US4713240A (en) *	1985-04-04	1987-12-15	Research Corporation	Vaccines based on insoluble supports
PT83095B (en) *	1985-07-30	1987-12-23	Int Minerals & Chem Corp	Method for the stabilization of growth promoting hormones using polyoxyethylene-polyoxypropylene copolymers
US4806352A (en) *	1986-04-15	1989-02-21	Ribi Immunochem Research Inc.	Immunological lipid emulsion adjuvant
US4877611A (en) *	1986-04-15	1989-10-31	Ribi Immunochem Research Inc.	Vaccine containing tumor antigens and adjuvants
US4803070A (en) *	1986-04-15	1989-02-07	Ribi Immunochem Research Inc.	Immunological emulsion adjuvants for polysaccharide vaccines
US5648071A (en) *	1986-05-15	1997-07-15	Emory University	Method of treating tumors
US5554372A (en) *	1986-09-22	1996-09-10	Emory University	Methods and vaccines comprising surface-active copolymers
US5811088A (en) *	1987-02-20	1998-09-22	Emory University	Antiinfective compounds and methods of use
US5674911A (en) *	1987-02-20	1997-10-07	Cytrx Corporation	Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
US5565209A (en) *	1987-03-17	1996-10-15	Akzo Nobel N.V.	Adjuvant mixture
ES2052685T3 (es) *	1987-03-17	1994-07-16	Akzo Nv	Metodo para producir un adyuvante libre.
US5376369A (en) *	1987-11-03	1994-12-27	Syntex (U.S.A.) Inc.	Vaccine adjuvant
NZ226811A (en) *	1987-11-03	1991-06-25	Syntex Inc	Adjuvant emulsion comprising a glycopeptide and non-toxic tetra-polyol or pop-poe block copolymer wherein oily particle size is less than 800am
DE3863908D1 (de) *	1987-11-27	1991-08-29	Akzo Nv	Stabilisierung von antikoerpern.
US5149529A (en) *	1988-04-08	1992-09-22	Board Of Trustees Of Leland Chiron Corporation	Compositions and treatment for herpes simplex
CA2017507C (en)	1989-05-25	1996-11-12	Gary Van Nest	Adjuvant formulation comprising a submicron oil droplet emulsion
NZ238731A (en) *	1990-06-27	1996-02-27	Univ Emory	Vaccine adjuvant compositions comprising ethyleneoxy-propyleneoxy-ethyleneoxy block copolymer or a non-toxic lipopolysaccharide
BR9106604A (pt) *	1990-06-29	1993-06-22	Chiron Corp	Composicao de vacina e processo para estimular uma resposta imunologica em um animal hospedeiro
FR2664813B1 (fr) *	1990-07-18	1995-01-13	Vacsyn France Sa	Compositions a base de substances hydrophobes, solubilisables dans un solvant aqueux, leur procede d'obtention, et leurs utilisations notamment dans le domaine pharmaceutique.
FR2672496B3 (fr) *	1990-07-18	1993-05-28	Vacsyn France Sa	Compositions a base de substances hydrophobes, solubilisables dans un solvant aqueux, leur procede d'obtention, et leurs utilisations notamment dans le domaine pharmaceutique.
US6933286B2 (en)	1991-03-19	2005-08-23	R. Martin Emanuele	Therapeutic delivery compositions and methods of use thereof
ES2140408T3 (es)	1991-03-19	2000-03-01	Cytrx Corp	Copolimeros de polioxipropileno/polioxietileno con actividad biologica mejorada.
US5696298A (en) *	1991-03-19	1997-12-09	Cytrx Corporation	Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US20020123476A1 (en) *	1991-03-19	2002-09-05	Emanuele R. Martin	Therapeutic delivery compositions and methods of use thereof
USRE38558E1 (en)	1991-03-19	2004-07-20	Cytrx Corporation	Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US7202225B1 (en)	1993-10-15	2007-04-10	Emanuele R Martin	Therapeutic delivery compositions and methods of use thereof
US5622649A (en) *	1991-06-27	1997-04-22	Emory University	Multiple emulsions and methods of preparation
ATE165749T1 (de) *	1991-06-27	1998-05-15	Univ Emory	Mehrkomponentemulsionen und verfahren zur deren herstellung
US6197311B1 (en)	1991-07-25	2001-03-06	Idec Pharmaceuticals Corporation	Induction of cytotoxic T-lymphocyte responses
US5342612A (en) *	1991-12-20	1994-08-30	American Cyanamid Company	Compositions for the treatment of mammalian diseases
JP3723231B2 (ja) *	1991-12-23	2005-12-07	ディミナコアクチェンゲゼルシャフト	アジュバント
AU3361093A (en) *	1992-01-20	1993-08-03	Peptech (Uk) Limited	Use of muramyl peptides for enhancing animal production
FR2702373B1 (fr) *	1993-03-08	1996-06-07	Rhone Merieux	Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
US5961970A (en) *	1993-10-29	1999-10-05	Pharmos Corporation	Submicron emulsions as vaccine adjuvants
GB9326253D0 (en) *	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
PT759780E (pt) *	1994-05-10	2001-01-31	American Home Prod	Vacina melhorada de vsrb vivo modificado
US6156319A (en) *	1994-07-25	2000-12-05	The Trustees Of The University Of Pennsylvania	Soluble herpesvirus glycoprotein complex vaccine
EP1181937A3 (de)	1994-08-09	2004-02-04	Cytrx Corporation	Nukleinsäure enthaltender Impfstoff, Impfstoff-adjuvans
PT750907E (pt) *	1995-06-30	2002-08-30	American Cyanamid Co	Formulacoes de vacinas estaveis para administracao parenterica metodo para a sua utilizacao e processo para a sua preparacao
ATE353225T1 (de) *	1995-11-30	2007-02-15	Chemo Sero Therapeut Res Inst	Öladjuvierter impfstoff und verfahren zu seiner herstellung
CA2259469A1 (en)	1996-06-05	1997-12-11	Ashmont Holdings Limited	Injectable compositions
PT973546E (pt) *	1997-04-08	2004-06-30	Merck & Co Inc	Formulacoes estabilizadas de virus de papiloma humano
AU769539B2 (en)	1999-01-29	2004-01-29	Zoetis Services Llc	Adjuvants for use in vaccines
JP5124066B2 (ja) *	1999-03-24	2013-01-23	イギリス国	ポリカチオン性炭水化物のワクチンにおける免疫賦活剤としての使用
SE9902364D0 (sv) *	1999-06-21	1999-06-21	Astra Ab	New process
US7018638B2 (en) *	2000-12-19	2006-03-28	Wyeth	Mycoplasma hyopneumoniae bacterin vaccine
MY129765A (en)	2000-12-19	2007-04-30	Wyeth Corp	Improved mycoplasma hyopneumoniae bacterin vaccine
EP1670508B1 (de)	2003-02-28	2012-10-24	Trustees Of The University Of Pennsylvania	Zusammensetzungen, verfahren und kits für pockenvirus-untereinheits-vakzine
AU2004226591B2 (en) *	2003-04-04	2009-06-04	Zoetis Services Llc	Microfluidized oil-in-water emulsions and vaccine compositions
CN101039691B (zh) *	2004-06-25	2013-07-31	魁北克益得生物医学公司	用于治疗神经疾病的组合物和方法
JP2008522951A (ja) *	2004-07-19	2008-07-03	ベイラー・カレツジ・オブ・メデイシン	サイトカインシグナル伝達調節物質の調節および免疫療法のための応用
US7868159B2 (en) *	2005-06-23	2011-01-11	Baylor College Of Medicine	Modulation of negative immune regulators and applications for immunotherapy
JP2009531462A (ja) *	2006-03-28	2009-09-03	ジェレシス，インク．	性能向上のためのポリマ材料と他の物質との併用
CN101678082B (zh)	2007-03-26	2013-06-19	再生医药有限公司	使用cxcl9和抗cxcl9抗体促进骨髓保护和再生的方法
JP5334462B2 (ja)	2007-06-11	2013-11-06	花王株式会社	脂肪酸エステルの製造法
JP2011505144A (ja) *	2007-11-30	2011-02-24	ベイラーカレッジオブメディシン	樹状細胞ワクチン組成物およびその使用
CA2744739A1 (en)	2007-12-03	2009-06-11	President And Fellows Of Harvard College	Chlamydia antigens
WO2011038002A1 (en)	2009-09-22	2011-03-31	Yale University	Immunogenic epitopes as targets for universal cancer vaccines
US20130116423A1 (en)	2010-04-23	2013-05-09	A. Stewart Campbell	Synthetic Oligosaccharides for Staphylococcus Vaccine
US8716469B2 (en)	2010-04-27	2014-05-06	Ancora Pharmaceuticals, Inc.	Synthetic oligosaccharides for Moraxella vaccine
WO2011149778A1 (en)	2010-05-26	2011-12-01	Ancora Pharmaceuticals Inc.	Synthetic oligosaccharides for neisseria meningitis vaccine
ES2657705T3 (es)	2010-06-23	2018-03-06	Deutsches Krebsforschungszentrum	Secuencias de virus TT específicas y moléculas de ADN quiméricas de células hospedadoras de virus TT para uso en el diagnóstico, prevención y tratamiento del cáncer y la autoinmunidad
EP2646459B1 (de)	2010-12-02	2020-01-08	Bionor Immuno AS	Peptidgerüstentwurf
JP6294076B2 (ja)	2011-01-06	2018-03-14	ビオノールイミュノエーエスＢｉｏｎｏｒＩｍｍｕｎｏＡｓ	多量体ペプチド
US9446112B2 (en)	2011-07-12	2016-09-20	Philadelphia Health & Education Corporation	Clostridium difficile DNA vaccine
US9120859B2 (en)	2012-04-04	2015-09-01	Zoetis Services Llc	Mycoplasma hyopneumoniae vaccine
UA114504C2 (uk)	2012-04-04	2017-06-26	Зоетіс Сервісіз Ллс	Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk)	2012-04-04	2017-06-26	Зоетіс Сервісіз Ллс	Комбінована вакцина pcv та mycoplasma hyopneumoniae
IN2014KN02769A (de)	2012-06-06	2015-05-08	Bionor Immuno As
JP5971652B2 (ja)	2012-10-09	2016-08-17	三菱重工業株式会社	石炭不活性化処理装置
EP2951199A4 (de)	2013-01-31	2016-07-20	Univ Jefferson	Fusionsproteine zur modulation von regulatorischen und effektor-t-zellen
WO2015116178A1 (en)	2014-01-31	2015-08-06	Thomas Jefferson University	Fusion proteins for modulating regulatory and effector t cells
EP2868751A1 (de)	2013-10-30	2015-05-06	Deutsches Krebsforschungszentrum	HCBI-Sequenzen als früher Marker für die zukünftige Entwicklung von Krebs und Erkrankungen des zentralen Nervensystems, und als Ziel zur Behandlung und Prävention von Krebs
EP2966176A1 (de)	2014-07-10	2016-01-13	Deutsches Krebsforschungszentrum	HCBIO-, MSBI-, MSSI- und CMI-Sequenzen als frühe Marker für die zukünftige Entwicklung von Krebs und Erkrankungen des ZNS und als Ziel zur Behandlung und Prävention dieser Erkrankungen
US20220089670A1 (en)	2018-12-28	2022-03-24	University Of Rochester	Gene Therapy for BEST1 Dominant Mutations
EP3686289A1 (de)	2019-01-24	2020-07-29	Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts	Cmi-sequenzen als frühmarker für die zukünftige entwicklung von krebs, atherosklerose, diabetes und erkrankungen des zns und als ziel für die behandlung und prävention dieser erkrankungen
WO2021160887A1 (en)	2020-02-14	2021-08-19	Immunor As	Corona virus vaccine
WO2025096754A1 (en)	2023-10-31	2025-05-08	Musc Foundation For Research Development	The use of enolase inhibitor pomhex for treatment of fibrosis
WO2026015821A1 (en)	2024-07-12	2026-01-15	University Of Rochester	Antibiotic alkaloid and methods of generating and use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2674619A (en) *	1953-10-19	1954-04-06	Wyandotte Chemicals Corp	Polyoxyalkylene compounds
US3867521A (en) *	1970-08-26	1975-02-18	Scherer Corp R P	Method for absorption of drugs
BE795516A (fr) *	1972-02-17	1973-08-16	Ciba Geigy	Preparations de peptides huileuses et injectables et procede pour leur preparation
US3869546A (en) *	1972-12-22	1975-03-04	Cutter Lab	Adjuvant compositions and medicinal mixtures comprising them
US4186194A (en) *	1973-10-23	1980-01-29	Agence Nationale De Valorisation De La Recherche (Anvar)	Water soluble agents effective as immunological adjuvants for stimulating, in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
US4370265A (en) *	1974-10-22	1983-01-25	Agence Nationale De Valorisation	Water soluble agents effective as immunological adjuvants for stimulating in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
IL48325A (en) *	1974-10-22	1979-05-31	Anvar	Immunological-free adjuvant compositions containing n-acetyl muramyl-alanyl-d-isoglutamine or n-acetyl-muramyl-l-alanyl-d-glutamicn acid
US4148869A (en) *	1975-03-06	1979-04-10	Baxter Travenol Laboratories, Inc.	Immunological reagent and method of using same
FR2313078A1 (fr) *	1975-02-07	1976-12-31	Anvar	Composition a base d'huile vegetale metabolisable et d'eau, utilisable notamment pour la constitution de preparations adjuvantes, ces preparations adjuvantes et leur procede d'obtention
US4082736A (en) *	1976-04-26	1978-04-04	Syntex (U.S.A.) Inc.	Novel immunological adjuvant compounds and methods of preparation thereof
US4082735A (en) *	1976-04-26	1978-04-04	Syntex (U.S.A.) Inc.	Novel immunological adjuvant compounds and methods of preparation thereof
GB1563561A (en) *	1976-06-23	1980-03-26	Daiichi Seiyaku Co	Muramyldipeptide derivatives and process for the preparation thereof
FR2358159A1 (fr) *	1976-07-16	1978-02-10	Anvar	Le diamide de l'acide 2-(2-acetamido-2-deoxy-3 - o-d-glucopyranosyl) - d-propionyl-l-alanyl-d-glutamique et medicaments le contenant
FR2368282A1 (fr) *	1976-10-22	1978-05-19	Anvar	Adjuvant immunologique constitue par le p-amino-phenyl de n-acetyl-muramyl-l-alanyl-d-isoglutamine
FR2428050A1 (fr) *	1978-06-05	1980-01-04	Anvar	Oligomeres de composes du type muramyl-peptide et medicaments les contenant
JPS5543030A (en) *	1978-09-21	1980-03-26	Dai Ichi Seiyaku Co Ltd	Prophylactic and remedy for microbial infection disease
FR2449697A1 (fr) *	1979-02-20	1980-09-19	Anvar	Nouveaux muramyl-peptides substitues sur un azote peptidique et medicaments les contenant
JPS55111499A (en) *	1979-02-21	1980-08-28	Takeda Chem Ind Ltd	Glucosamine derivative and its preparation
CA1185237A (en) *	1979-02-28	1985-04-09	Yuichi Yamamura	6-deoxyglucosamine-peptide derivatives, their production and use
US4384974A (en) *	1979-07-27	1983-05-24	Revlon, Inc.	Stable water-in-oil emulsions
US4409209A (en) *	1979-10-12	1983-10-11	Ciba-Geigy Corporation	Novel phosphorylmuramyl peptides and processes for the manufacture thereof
FI803077A7 (fi) *	1979-10-12	1981-04-13	Ciba Geigy Ag	Foerfarande foer framstaellning av myramylpeptider
US4406889A (en) *	1980-02-15	1983-09-27	Ciba-Geigy Corporation	Derivatives of aldohexoses, intermediates, processes for their manufacture, preparations containing such compounds, and their use
GR78246B (de) *	1981-01-23	1984-09-26	Ciba Geigy Ag
US4397870A (en) *	1982-07-27	1983-08-09	The University Of Pennsylvania	Process for prolonging retention of emulsion particles in the bloodstream
US4606918A (en) *	1983-08-22	1986-08-19	Syntex (U.S.A.) Inc.	Polyoxypropylene-polyoxyethylene block polymer based adjuvants

1983
- 1983-08-22 US US06/525,190 patent/US4606918A/en not_active Expired - Lifetime
1984
- 1984-08-20 PH PH31121A patent/PH21112A/en unknown
- 1984-08-21 ZA ZA846504A patent/ZA846504B/xx unknown
- 1984-08-21 NZ NZ209293A patent/NZ209293A/xx unknown
- 1984-08-21 IL IL72740A patent/IL72740A/xx not_active IP Right Cessation
- 1984-08-21 CA CA000461465A patent/CA1236017A/en not_active Expired
- 1984-08-21 DK DK400684A patent/DK167173B1/da not_active IP Right Cessation
- 1984-08-21 EP EP84305687A patent/EP0135376B1/de not_active Expired - Lifetime
- 1984-08-21 IE IE214884A patent/IE58035B1/en not_active IP Right Cessation
- 1984-08-21 AT AT84305687T patent/ATE58062T1/de not_active IP Right Cessation
- 1984-08-21 JP JP59174861A patent/JPH0617314B2/ja not_active Expired - Lifetime
- 1984-08-21 AU AU32251/84A patent/AU578907B2/en not_active Expired
- 1984-08-21 DE DE8484305687T patent/DE3483553D1/de not_active Expired - Lifetime
1992
- 1992-10-22 HK HK823/92A patent/HK82392A/en not_active IP Right Cessation
1993
- 1993-08-17 JP JP5203231A patent/JP2557603B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP2557603B2 (ja)	1996-11-27
EP0135376B1 (de)	1990-11-07
DK400684D0 (da)	1984-08-21
ATE58062T1 (de)	1990-11-15
AU3225184A (en)	1985-02-28
ZA846504B (en)	1986-03-26
AU578907B2 (en)	1988-11-10
EP0135376A3 (en)	1986-12-30
DE3483553D1 (de)	1990-12-13
IE842148L (en)	1985-02-22
US4606918A (en)	1986-08-19
DK400684A (da)	1985-02-23
DK167173B1 (da)	1993-09-13
JPH0617314B2 (ja)	1994-03-09
PH21112A (en)	1987-07-16
JPH0665097A (ja)	1994-03-08
IE58035B1 (en)	1993-06-16
IL72740A0 (en)	1984-11-30
JPS60105630A (ja)	1985-06-11
CA1236017A (en)	1988-05-03
EP0135376A2 (de)	1985-03-27
HK82392A (en)	1992-10-30
NZ209293A (en)	1988-10-28

Legal Events

Date	Code	Title
1999-01-26	KB	Patent renewed
2002-09-12	KB	Patent renewed
2004-11-10	EXP	Patent expired

Publication	Publication Date	Title
IL72740A (en)	1988-02-29	Adjuvant compositions comprising polyoxypropylene-polyoxyethylene block polymers,vaccine compositions containing them and methods for enhancing the immunogenicity of antigens
PT1140165E (pt)	2009-01-13	Composições de adjuvante de saponina melhoradas e métodos relacionados
HU900653D0 (en)	1990-04-28	Process for preparing vaccines containing tocholes as adjuvants
SE8903777D0 (sv)	1989-11-10	Liposome/doxorubicin, komposition och foerfarande
EP0362279A4 (de)	1990-05-14	Saponin-hilfsmittel.
MX9302199A (es)	1994-08-31	Aditivo para vacuna.
GB2303855B (en)	1998-10-28	Helicobacter pylori antigenic protein preparation and immunoassays
PL304419A1 (en)	1995-01-09	Urease based vaccine against heliobacter infections
EP0489153A4 (en)	1993-04-21	Vaccine compositions containing liposomes
ATE103180T1 (de)	1994-04-15	Impfstoff-zubereitung.
AU4195897A (en)	1998-04-02	Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and methods of preparation thereof
ATE149091T1 (de)	1997-03-15	Einen tetra-polyol enthaltendes impfstoff- adjuvans
DE3269188D1 (en)	1986-03-27	Vaccine for hepatitis
JPS5693755A (en)	1981-07-29	Cold curing organopolysiloxane composition
Malangoni et al.	1983	Survival after bacterial challenge correlates with splenic weight.
RU93005000A (ru)	1996-10-27	Композиция вакцин, способ ее получения, способ исключения иммунной реакции
SU961186A1 (ru)	2000-03-27	Адъювант
IT8235971V0 (it)	1982-07-30	Dispositivo di aspirazione per uso rianimatorio, integrabile in particolare all'attrezzatura per immersione subacquea